Similarly, analysis of combined FIGHT-202 (n = 104) and FIGHT-207 (n = 11) data for patients with cholangiocarcinoma (Supplementary Table 6) did not result in any change to the identification of co-altered genes significantly correlated with best overall response to pemigatinib, and only TP53 was found to be nominally significant (significance was not maintained following stringency correction for multiple testing). Here, TP53 is linked to cholangiocarcinoma.